Neurocrine Biosciences Inc
NASDAQ:NBIX

Watchlist Manager
Neurocrine Biosciences Inc Logo
Neurocrine Biosciences Inc
NASDAQ:NBIX
Watchlist
Price: 125.51 USD -1.18% Market Closed
Market Cap: 12.7B USD
Have any thoughts about
Neurocrine Biosciences Inc?
Write Note

Wall Street
Price Targets

NBIX Price Targets Summary
Neurocrine Biosciences Inc

Wall Street analysts forecast NBIX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NBIX is 165.76 USD with a low forecast of 115.14 USD and a high forecast of 201.6 USD.

Lowest
Price Target
115.14 USD
8% Downside
Average
Price Target
165.76 USD
32% Upside
Highest
Price Target
201.6 USD
61% Upside

NBIX Last Price Targets
Neurocrine Biosciences Inc

The latest public price target was made on Oct 31, 2024 by Evan David Seigerman from BMO Capital , who expects NBIX stock to drop by 4% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Evan David Seigerman
BMO Capital
121 USD
Downside 4%
2 weeks ago
Oct 31, 2024
Neurocrine Bio. (NBIX) PT Raised to $121 at BMO Capital
StreetInsider
Jay Olson
Oppenheimer
192 USD
Upside 53%
3 weeks ago
Oct 22, 2024
Oppenheimer Reiterates Outperform Rating on Neurocrine Bio. (NBIX)
StreetInsider
Danielle Brill
Raymond James
155 USD
Upside 23%
1 month ago
Oct 10, 2024
Neurocrine resumed with an Outperform at Raymond James
TheFly
Evan David Seigerman
BMO Capital
128 USD
Upside 2%
2 months ago
Sep 13, 2024
BMO Capital Reiterates Market Perform Rating on Neurocrine Bio. (NBIX)
StreetInsider
Carter Gould
Barclays
160 USD
Upside 27%
2 months ago
Sep 9, 2024
Neurocrine price target lowered to $160 from $180 at Barclays
TheFly
Brian Abrahams
RBC Capital
136 USD
Upside 8%
2 months ago
Aug 29, 2024
Neurocrine price target lowered to $136 from $143 at RBC Capital
TheFly
David Amsellem
Piper Sandler
159 USD
Upside 27%
2 months ago
Aug 29, 2024
Piper Sandler Upgrades Neurocrine Bio. (NBIX) to Overweight
StreetInsider
Jeffrey Hung
Morgan Stanley
170 USD
Upside 35%
4 months ago
Jul 12, 2024
Neurocrine price target raised to $170 from $160 at Morgan Stanley
TheFly
Brian Abrahams
RBC Capital
141 USD
Upside 12%
5 months ago
Jun 6, 2024
RBC Capital Reiterates Sector Perform Rating on Neurocrine Bio. (NBIX)
StreetInsider
Ashwani Verma
UBS
193 USD
Upside 54%
5 months ago
May 28, 2024
Neurocrine Bio. (NBIX) PT Raised to $193 at UBS
StreetInsider
Cory Kasimov
Evercore ISI
175 USD
Upside 39%
6 months ago
May 13, 2024
Neurocrine initiated with an Outperform at Evercore ISI
TheFly
Sumant Kulkarni
Canaccord Genuity
164 USD
Upside 31%
6 months ago
May 2, 2024
Neurocrine price target raised to $164 from $154 at Canaccord
TheFly
Andrew Fein
H.C. Wainwright
160 USD
Upside 27%
6 months ago
May 2, 2024
Neurocrine Bio. (NBIX) PT Raised to $160 at H.C. Wainwright
StreetInsider
Mohit Bansal
Wells Fargo
170 USD
Upside 35%
6 months ago
Apr 23, 2024
Wells Fargo Upgrades Neurocrine Bio. (NBIX) to Overweight 'as the Company is Knocking on the Doors of the Large-Cap Club'
StreetInsider
Jay Olson
Oppenheimer
200 USD
Upside 59%
8 months ago
Mar 12, 2024
Neurocrine Bio. (NBIX) PT Raised to $200 at Oppenheimer, 'increasingly optimistic for NBIX's M4 agonist ahead of Ph2 topline results'
StreetInsider
Unknown Analyst
Morgan Stanley
130 USD
Upside 4%
1 year ago
Feb 3, 2023
Morgan Stanley Upgrades Neurocrine Biosciences to Overweight, Raises Price Target to $130
Benzinga
Show More Price Targets
Show Less Price Targets
Evan David Seigerman
BMO Capital
Price Target 121 USD
Upside/Downside 4%
View Source
Jay Olson
Oppenheimer
Price Target 192 USD
Upside/Downside 53%
View Source
Danielle Brill
Raymond James
Price Target 155 USD
Upside/Downside 23%
View Source
Evan David Seigerman
BMO Capital
Price Target 128 USD
Upside/Downside 2%
View Source
Carter Gould
Barclays
Price Target 160 USD
Upside/Downside 27%
View Source
Brian Abrahams
RBC Capital
Price Target 136 USD
Upside/Downside 8%
View Source
David Amsellem
Piper Sandler
Price Target 159 USD
Upside/Downside 27%
View Source
Jeffrey Hung
Morgan Stanley
Price Target 170 USD
Upside/Downside 35%
View Source
Brian Abrahams
RBC Capital
Price Target 141 USD
Upside/Downside 12%
View Source
Ashwani Verma
UBS
Price Target 193 USD
Upside/Downside 54%
View Source
Cory Kasimov
Evercore ISI
Price Target 175 USD
Upside/Downside 39%
View Source
Sumant Kulkarni
Canaccord Genuity
Price Target 164 USD
Upside/Downside 31%
View Source
Andrew Fein
H.C. Wainwright
Price Target 160 USD
Upside/Downside 27%
View Source
Mohit Bansal
Wells Fargo
Price Target 170 USD
Upside/Downside 35%
View Source
Jay Olson
Oppenheimer
Price Target 200 USD
Upside/Downside 59%
View Source
Unknown Analyst
Morgan Stanley
Price Target 130 USD
Upside/Downside 4%
View Source
Show More Price Targets
Show Less Price Targets
Neurocrine Biosciences Inc Competitors:
Price Targets
DSGN
Design Therapeutics Inc
5% Downside
OXB
Oxford BioMedica PLC
17% Upside
NANO
Nanobiotix SA
235% Upside
ARGX
argenx SE
7% Downside
1801
Innovent Biologics Inc
59% Upside
XNCR
Xencor Inc
49% Upside
NRIX
Nurix Therapeutics Inc
16% Upside
4893
Noile-Immune Biotech Inc
172% Upside

Revenue
Forecast

Revenue Estimate
Neurocrine Biosciences Inc

For the last 8 years the compound annual growth rate for Neurocrine Biosciences Inc's revenue is 77%. The projected CAGR for the next 3 years is 20%.

77%
Past Growth
20%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Neurocrine Biosciences Inc

The compound annual growth rate of Neurocrine Biosciences Inc's operating income for the next 3 years is 46%.

N/A
Past Growth
46%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Neurocrine Biosciences Inc

The compound annual growth rate of Neurocrine Biosciences Inc's net income for the next 3 years is 53%.

N/A
Past Growth
53%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NBIX's stock price target?
Price Target
165.76 USD

According to Wall Street analysts, the average 1-year price target for NBIX is 165.76 USD with a low forecast of 115.14 USD and a high forecast of 201.6 USD.

What is Neurocrine Biosciences Inc's Revenue forecast?
Projected CAGR
20%

For the last 8 years the compound annual growth rate for Neurocrine Biosciences Inc's revenue is 77%. The projected CAGR for the next 3 years is 20%.

What is Neurocrine Biosciences Inc's Operating Income forecast?
Projected CAGR
46%

The compound annual growth rate of Neurocrine Biosciences Inc's operating income for the next 3 years is 46%.

What is Neurocrine Biosciences Inc's Net Income forecast?
Projected CAGR
53%

The compound annual growth rate of Neurocrine Biosciences Inc's net income for the next 3 years is 53%.

Back to Top